#VisualAbstract: Effect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients With Sepsis and Severe Acute Respiratory Failure

1. In this randomized clinical trial, intravenous infusion of high-dose vitamin C vs placebo for 96 hours resulted in no significant differences in the modified Sequential Organ Failure Assessment score at 96 hours or in levels of C-reactive protein and thrombomodulin at 168 hours.

2. There were three secondary outcomes which were significantly different between groups but lacked adjustment of multiple comparisons.

Evidence Rating Level: 1 (Excellent)

Study Rundown:Acute respiratory distress syndrome (ARDS) is a common complication in sepsis which contributes to multi-organ dysfunction and mortality. Currently, research has shown the possibility that vitamin C can reduce inflammation and reverse sepsis-induced coagulopathy. In this randomized trial, CITRIS-ALI, patients with sepsis and ARDS in the intensive care unit who received high-dose vitamin C did not have lower rates of organ failure and biomarkers of inflammation and vascular injury.

There needs to be more research on vitamin C’s use in sepsis and ARDS. The study has several limitations. First, CITRIS-ALI was based on a previously performed vitamin C safety trial of vitamin C administered to patients in the very early stages of severe sepsis and not ARDS. This trial’s ARDS patients underwent intubation, which could have delayed vitamin C administration. Second, this trial may have been underpowered to detect a difference in modified Sequential Organ Failure Assessment (mSOFA) scores and biomarker levels. The dosage of vitamin C used in this trial (50mg/kg every 6 hours for 96 hours) may also be insufficient for optimal care of sepsis associated ARDS. Higher vitamin C dosages or longer administration times may have produced different results. Lastly, because death and ICU graduation rates between the 2 groups were not similar, there could be internal selection bias.

2 Minute Medicine® is an award winning, physician-run, expert medical media company originally founded out of Harvard Medical School and the Massachusetts Institute of Technology.
Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians.
Join numerous brands, companies, and hospitals who trust our licensed content.